PharmaLectures.com

Courses › Pharma training by country › Same molecule, different rulebook: Japanese regulation versus the EU

Same molecule, different rulebook: Japanese regulation versus the EU

Your Japanese team files in Europe once, and the dossier clears validation.

  • 8 audio modulesthree lengths each
  • 1 h 20 min to 6 h 40 minbriefing to expanded
  • Workbook, transcript, certificateand a recorded quiz per module
  • Japan companieswho it is written for

Why this training matters

Your regulatory team sends the European Medicines Agency a dossier built on Japanese data. Validation stops because Module 1, the regional part of the Common Technical Document, is incomplete. The launch waits while the team rebuilds the file, and your European partner asks for a new date.

What changes after this course

Your team builds every European submission in the right format on the first pass and answers inspectors with the exact EudraLex Volume 4 reference. You hold a certificate for each learner and a training record for each person.

Watch the pitch

3:43 on how an audio course is bought, listened to and recorded. Full screen, one click.

Watch the pitch3:43, full screen, one click

What this course gives your people

A dossier built on Pharmaceuticals and Medical Devices Act data no longer goes to Europe on hope. Your regulatory team checks Module 1 of the Common Technical Document before filing, builds Module 3 in the order reviewers expect, and decides early between the centralised and decentralised route. The file passes validation, and the launch date holds.

At the Clinical Trials Information System, the clinical operations group stops finding errors one rejection at a time. They file Part I and Part II of the European Clinical Trial Application correctly, and they settle where a Japanese consent form and European Good Clinical Practice rules disagree before a site is asked to open. The questions that come back are about the science, not a missing field.

Factory and quality managers read EudraLex Volume 4 and revised Annex 1 against their own plant, room by room, and write the Contamination Control Strategy that sterile products need. When a deviation happens, the record already holds what the Qualified Person asks for under Annex 16, so the batch ships instead of waiting for a clarification. The management review in International Council for Harmonisation Q10 shows the site its own deviation trends before an inspector does.

Pharmacovigilance and device colleagues keep a Pharmacovigilance System Master File that answers an inspector's first question, with a Qualified Person for Pharmacovigilance named in Europe. Risk management plans follow Good Pharmacovigilance Practices Module V, devices are classified under Annex VIII of the Medical Device Regulation, and when an inspector asks, the answer comes with the exact reference and a document to hand over.

Who needs this training

  • Regulatory Affairs Manager

    Sits down to compile the European Marketing Authorisation Application and sees at once which Japanese documents feed Module 3 and what Module 1 needs, without calling an outside consultant to restructure the file.

  • Quality Assurance Director

    An inspector asks to see the pharmaceutical quality system, and the director opens a management review and a Contamination Control Strategy that already match International Council for Harmonisation Q10 and Annex 1.

  • Clinical Operations Lead

    Drafts the European Clinical Trial Application with Part I and Part II in hand, and settles the Japanese and European informed consent differences before the first site is asked to open.

  • Pharmacovigilance Specialist

    An inspector opens the Pharmacovigilance System Master File, and the specialist points straight to the Qualified Person's details and the safety database without hunting for the section.

  • Medical Device Regulatory Lead

    Receives a new device and sets its class under Annex VIII of the Medical Device Regulation in one sitting, then knows whether a notified body must be called in.

Roles: Regulatory affairs, Quality assurance and Qualified Person

Businesses: every kind of pharma company

Countries: Japan

Selling into: Europe and the UK

Courses are in English. Other languages on request.

After this course your people can

  1. Map each duty under the Pharmaceuticals and Medical Devices Act to its European counterpart.
  2. Complete a European Clinical Trial Application in the Clinical Trials Information System with Part I and Part II documents in the right place.
  3. Lay out Module 3 of the Common Technical Document and choose between the centralised and decentralised procedure for a given product.
  4. Write a Contamination Control Strategy that answers the revised Annex 1 and record a deviation in the form the Qualified Person needs under Annex 16.
  5. Draft a Pharmacovigilance System Master File and name the Qualified Person for Pharmacovigilance with the details an inspector will check.
  6. Classify a device under Annex VIII of the Medical Device Regulation and say whether a notified body is required.
  7. Answer an inspector's question about EudraLex Volume 4 with the exact chapter and write a response that can close the observation.

What the company gets

  • Your European filings reach the European Medicines Agency in a form it can validate, so the launch date no longer depends on a rewrite.
  • Your sterile batches carry a deviation record the Qualified Person can certify under Annex 16, so shipments stop waiting on follow-up questions.
  • Your quality team keeps an Annex 1 Contamination Control Strategy and an International Council for Harmonisation Q10 management review ready for the day an inspector asks.
  • You show an inspector who was trained, on which module, and when, because each learner has a certificate and a training record.

The evidence: questionnaire, training record, certificate

EU GMP Chapter 2, section 2.11, and 21 CFR 211.25 both ask for training that is documented and shown to work. This is what each learner leaves behind.

A recorded questionnaire per module

Every one of the 8 modules ends with a multiple-choice questionnaire. The result is recorded per person with a timestamp, whichever of the three lengths the person listened to.

A per-person training record

The export lists each learner, each module, the result and the date, which is the training record EU GMP Chapter 2 and 21 CFR 211.25 ask you to keep and the first thing an inspector asks for.

A certificate per learner

Name, company, course, hours, the guideline version taught and the date. It documents in-company training; it is not a professional qualification or an accreditation.

Your pass mark, your rule

There is no fixed pass mark. Your quality or human-resources manager decides what counts as passed and when a module is retaken, exactly as your training procedure says.

Delivered within 72 hours of payment, with the workbook, the full transcript and a source for every fact in the audio.

How long it takes, by who is listening

Nobody spends a day in a classroom. Every module exists in three lengths; a person takes the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Briefing1 h 20 min10 min a module, for executives, sales and anyone who must know the rules, not run them
Standard3 h 20 min25 min a module, for regulatory, quality and business-development staff
Expanded6 h 40 min50 min a module, for technical staff who run the procedure day to day
Who takes this courseLengthTotal time
Regulatory affairsStandard3 h 20 min
Quality assurance and Qualified PersonStandard3 h 20 min

Course outline: 8 modules

8 modules. Under each title are the three things the listener can do afterwards; the audio itself runs 10 to 50 minutes depending on the length chosen.

  1. 1Map Japanese rules onto European regulatory frameworks

    • Why a dossier accepted in Japan still stops at European validation, and how to catch it first.
    • How to find the European counterpart of each duty under the Pharmaceuticals and Medical Devices Act.
    • Where the European Commission decides, and where each member state keeps its own say.
  2. 2Submit your European Clinical Trial Application with no database errors

    • How to build the application in the Clinical Trials Information System so it passes validation first time.
    • Why the application splits into Part I and Part II, and which of your documents lands in each.
    • What to do when your Japanese consent form and European consent rules ask for different things.
  3. 3Build a European Marketing Authorisation Application that reviewers approve

    • When the centralised procedure is compulsory for your product and when decentralised is open to you.
    • How to lay out Module 3, the quality section, the way European reviewers expect it.
    • The variation types in Commission Regulation 1234/2008 that tell you to notify or wait for approval.
  4. 4Align your Japanese factory with European Good Manufacturing Practice

    • The Contamination Control Strategy that revised Annex 1 asks your site to write down and defend.
    • How to trace each EudraLex Volume 4 requirement to the room, procedure or record in your own plant.
    • Why Annex 16 batch certification can hold your shipment, and which records let the Qualified Person sign.
  5. 5Satisfy International Council for Harmonisation Q10 in your quality system

    • The management review that International Council for Harmonisation Q10 requires, and what to put in it.
    • How to record a quality defect so the Qualified Person signs without a second round of questions.
    • Why a Japanese responsible person cannot take over the duties of a European Qualified Person.
  6. 6Keep your Pharmacovigilance System Master File compliant and inspection ready

    • How to keep the Pharmacovigilance System Master File current so it answers an inspector's first question.
    • Why the Qualified Person for Pharmacovigilance must reside and work in Europe, and what to document.
    • What to change in a Japanese risk management plan to meet Good Pharmacovigilance Practices Module V.
  7. 7Classify your devices under the European Union Medical Device Regulation

    • How to use the classification rules in Annex VIII to place each device in its European class.
    • When your device needs a notified body and when the manufacturer can declare conformity alone.
    • The post-market surveillance plan that Article 84 requires, and the data it must collect.
  8. 8Answer European inspectors before they write an observation

    • The first questions an inspector asks about a deviation, and the record you hand over to answer them.
    • How to test your own site against EudraLex Volume 4 before the inspector does.
    • What to write in your response so the observation can close without a second request.
The founders

One of us was inspected. The other one pays for the training.

Every claim below is sourced on the about page: the medicines register, the Lithuanian Pharmaceutical Union board list, the university directory.

Justina Krukonytė-Racz

Justina Krukonytė-Racz

Co-founder. Licensed pharmacist.

GDPResponsible PersonWarehouse & logistics

Licensed pharmacist. Responsible Person at Tamro (PHOENIX group), where she led the GDP set-up of the distribution centre.

The Responsible Person is the named person the regulator holds accountable for every pallet that leaves the building.

She writes the modules around the procedures a GDP inspection checks. Board member of Lithuanian Pharmaceutical Union.

Listed in the Lithuanian medicines register as Pharmacist.

Prof. Ben Racz

Prof. Ben Racz

Co-founder. Builds the platform and is responsible for delivery, records and pricing.

Platform & deliveryQuantitative researchCarnegie Mellon

He was Professor of the Practice at the College of Engineering at Carnegie Mellon University, where he taught Advanced Quantitative Finance and Algorithmic Trading to MSc students.

He is the founder and Managing Director of Algorithmic Sciences, a scientific research and consulting firm. Earlier he co-founded a data-driven growth consultancy, a data-science based wholesale trading company and an information security firm.

More about Ben at benracz.com

Questions about this course

Is there a certificate?

Yes. Every learner who finishes the course receives a certificate in their own name, and every module ends with a recorded multiple-choice questionnaire, so the certificate sits on top of a per-person training record. The certificate documents in-company training; it is not a professional qualification or an accreditation, and your quality or human-resources manager sets the pass mark and decides when a module is retaken.

How long does the course take?

8 modules, each in three lengths: a 10-minute briefing, a 25-minute standard run and a 50-minute expanded walk-through. The whole course takes 1 h 20 min in the briefing length and 6 h 40 min in the expanded length. People take the length their role needs, and every length ends with the same recorded questionnaire, so the training record is complete either way.

Who should take this course?

It is written for Japan companies. Owners, managers and sales staff hear the briefing length, regulatory, quality and business-development staff take the standard run, and the people who run the procedure every day get the expanded version. One licence covers one named person on this course for a year, so the same title can be rolled out across a whole team at once.

Is this training accepted as a GMP training record by an auditor?

EU GMP Chapter 2 and 21 CFR 211.25 require documented, effective training, and that is what the course produces: a recorded multiple-choice result per module and per person, a certificate per learner and a transcript of what was taught. No provider can promise acceptance by a specific inspector; the record is built to answer what inspectors ask for, and your quality manager decides the pass mark.

How is it delivered and how fast?

The course arrives as audio files with a companion workbook, a full transcript and the questionnaire per module, within 72 hours of your payment arriving. You host the files on your own system or share them as you like; there is no platform to log into and no learner management system to set up. The free sample module arrives on request, before any purchase.

What does it cost per learner?

The list price is 9 euros per module, per learner, per year, so this course is 72 euros for one person for twelve months. The price per learner falls as more people take the same course: 10 learners pay 10 percent less and the discount keeps growing to 50 percent at 1000 learners. Type a number on the price panel and the yearly total appears.

Get this course for your team

One licence is one person on this course for a year. All three lengths, the workbook, the certificate and the training record are included in every purchase. Pick how many people, add it to the cart, and you have an invoice in your inbox.

Free sample module

Hear one full module before you spend a cent. Send your company and the role you want trained, and a complete sample module comes back with its workbook and transcript.

Connect on WhatsApp

or email [email protected], or ask for a written quote for your team